Intestinal Ultrasound Predicts Primary Non‐Response and Maintenance Relapse in Upadacitinib‐Treated Active Crohn's Disease: A Multicenter, Prospective Cohort Study
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70948 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Renbin He und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Crohn Disease, Gastrointestinal Agents, Intestines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Intestinal ultrasound (IUS) is increasingly used to monitor activity and predict treatment outcomes in Crohn's disease (CD), but its role in predicting primary non‐response (PNR) to Upadacitinib (UPA) and identifying maintenance relapse remains unclear.
Methods
In this multicenter prospective cohort study, 122 patients with active CD treated with UPA were followed through week 52. Demographic, clinical, biochemical, endoscopic and IUS data were collected longitudinally. Univariable logistic regression, ROC analysis and likelihood ratio test (LRT) identified the best PNR predictors. Survival analysis evaluated the association between post‐induction ultrasound targets and the risk of relapse during 15‐mg maintenance.
Results
Among baseline IUS parameters, IBUS‐SAS > 60.20 demonstrated the highest odds ratio for predicting UPA PNR (OR 16.63, 95% CI 6.54–42.29, p < 0.001). Compared with clinical and endoscopic parameters, the inclusion of IBUS‐SAS significantly improved PNR prediction (AUC 0.865 vs. 0.670, LRT p < 0.001, 95% CI 0.802–0.929, Sensitivity 82.98%, Specificity 77.33%, PPV 69.64% and NPV 87.88%). Early at week 4, worse IUS findings were significantly correlated with PNR, with IBUS‐SAS > 47.80 showing the highest odds ratio (OR 26.25, 95% CI 2.46–280.20, p = 0.007). Among clinical and endoscopic responders, failure to achieve IUS response/remission was associated with an increased risk of relapse during 15‐mg maintenance. (Log‐rank p = 0.005, p < 0.001).
Conclusion
Early IUS monitoring provides incremental value for predicting UPA PNR beyond clinical and endoscopic parameters. Failure to achieve IUS response/remission may identify patients at increased risk of relapse during 15‐mg maintenance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Medical Ultrasonics, The Third Xiangya Hospital, Central South University, Changsha, China.
- Xiangya School of Medicine, Central South University, Changsha, China.
ORCID-Profile: Renbin He, Jing Han, Shiyin Jiang, Kang Chao, Li Tian
Zitieren
APA
He, R., Huang, Y., Han, J., Zhao, P., Xin, C., Xiong, Z., Ma, D., Mao, X., Meng, T., Jiang, S., Wu, Y., Lei, X., He, Y., Gao, F., Wang, X., Chao, K., & Tian, L. (2026). Intestinal Ultrasound Predicts Primary Non‐Response and Maintenance Relapse in Upadacitinib‐Treated Active Crohn's Disease: A Multicenter, Prospective Cohort Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70948
Vancouver
He R, Huang Y, Han J, Zhao P, Xin C, Xiong Z, et al. Intestinal Ultrasound Predicts Primary Non‐Response and Maintenance Relapse in Upadacitinib‐Treated Active Crohn's Disease: A Multicenter, Prospective Cohort Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70948
BibTeX
@article{He2026,
author = {He, Renbin and Huang, Yuanyuan and Han, Jing and Zhao, Panpan and Xin, Chang and Xiong, Zili and Ma, Ding and Mao, Xiayu and Meng, Tianjing and Jiang, Shiyin and Wu, Yuwei and Lei, Xihao and He, Yayi and Gao, Feng and Wang, Xiaoyan and Chao, Kang and Tian, Li},
title = {Intestinal Ultrasound Predicts Primary Non‐Response and Maintenance Relapse in Upadacitinib‐Treated Active Crohn's Disease: A Multicenter, Prospective Cohort Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70948}
}
EUVIMED